CN114106155B

CN114106155B - Monoclonal antibody of African swine fever virus P22 protein and application thereof

Info

Publication number: CN114106155B
Application number: CN202010863617.1A
Authority: CN
Inventors: 田克恭; 颜世君; 黄甜
Original assignee: Luoyang Pu Tai Biotechnology Co ltd
Current assignee: Luoyang Pu Tai Biotechnology Co ltd
Priority date: 2020-08-25
Filing date: 2020-08-25
Publication date: 2023-06-13
Anticipated expiration: 2040-08-25
Also published as: CN114106155A

Abstract

The invention relates to a monoclonal antibody of an African swine fever virus P22 protein and application thereof. The amino acid sequence of the heavy chain variable region of the monoclonal antibody provided by the invention is shown as SEQ ID No.2, and the amino acid sequence of the light chain variable region is shown as SEQ ID No. 4. The variable region sequence of the monoclonal antibody provided by the invention can be specifically and conservatively combined with the African swine fever virus P22 protein, can be used for immunohistochemical detection of a plurality of tissues with high titer, has clean background and has wide application prospect.

Description

Monoclonal antibody of African swine fever virus P22 protein and application thereof

Technical Field

The invention belongs to the field of virus epidemic disease diagnosis technology and animal quarantine, and particularly relates to a monoclonal antibody of an African swine fever virus P22 protein and application thereof.

Background

African swine fever (African swine fever, ASF) is an acute, febrile, highly contagious infectious disease of pigs caused by African swine fever virus (African swine fever virus, ASFV), and is characterized clinically by hyperpyrexia, anorexia, and bleeding of skin and internal organs (similar to swine fever), and has the advantages of short disease course, high morbidity, high mortality (up to 100%), particularly more infectious sources, more transmission routes, more transmission modes, and serious damage once occurring. ASF was first discovered in kenya in 1921, and later the presence of ASFV was found in many countries both in the south africa and in the east. Since the first diagnosis in China in 8 months and 3 days of 2018 occurs in African swine fever epidemic situation in Shen Beixin area of Shenyang city of Shenyang, liaoning province, african swine fever rapidly spreads in various provinces and cities in China, the epidemic situation is continuously expanded, and once the diagnosis is confirmed, treatment measures such as blocking, killing, harmless treatment, disinfection and the like are required, so that the influence on the whole industry is seismic grade. ASF reports animal epidemic diseases for animals in the world by legal animal health Organization (OIE), which is a disease of animals specified in China, and is highly valued in the world.

ASFV is the only member of African swine fever virus family, african swine fever virus genus, is the only DNA arbovirus known at present, is a single-molecule linear double-stranded DNA virus with a capsule, has a genome length of about 170kb-193kb, is one of the largest viruses in animal viruses, and has a genome 24 times that of foot-and-mouth disease virus and 15 times that of swine fever virus. African swine fever virus P22 protein (ASFV P22 protein), also called KP177R, is a 22kD protein encoded by ORF KP177R gene, and is a main structural protein of ASFV, and the specific function is not clear. ASFV infects mainly pigs and wild boars and replicates both in vertebrates and invertebrates. The lack of effective vaccines and specific treatments currently makes ASF one of the most serious epidemic diseases that currently jeopardizes the pig industry. Control of ASF currently relies on rapid diagnosis, killing of diseased animals, and effective quarantine and strict sanitation.

Disclosure of Invention

Aiming at the defects of the prior art, the invention provides a monoclonal antibody specifically combined with an African swine fever virus P22 protein and application thereof.

In a first aspect the invention provides a variable region sequence of an antibody or antibody fragment which specifically binds to the P22 protein of african swine fever virus, said variable region sequence comprising the amino acid sequence shown in seq id No.2 or a conservative variant thereof and the amino acid sequence shown in seq id No.4 or a conservative variant thereof.

According to the invention, conservative variants of an amino acid sequence may be obtained by one or more amino acid additions, deletions, substitutions or modification of conservative mutations.

According to the invention, the variable region sequence is capable of specifically binding to the African swine fever virus P22 protein.

According to some embodiments of the invention, the antibody is a monoclonal antibody or a genetically engineered antibody.

According to a preferred embodiment of the invention, the antibody is a monoclonal antibody.

According to some embodiments of the invention, the antibody is a single chain antibody whose heavy chain variable region is encoded by the sequence shown in SEQ ID No.3 or a degenerate sequence thereof and whose light chain variable region is encoded by the sequence shown in SEQ ID No.5 or a degenerate sequence thereof.

According to some embodiments of the invention, the genetically engineered antibody comprises one or more selected from the group consisting of single chain antibodies, chimeric monoclonal antibodies, reshaped monoclonal antibodies, and swine-derived monoclonal antibodies.

In a second aspect, the invention provides an antibody or antibody fragment which specifically binds to the P22 protein of african swine fever virus, wherein the antibody or antibody fragment comprises the heavy chain variable region of the amino acid sequence shown in seq id No.2 or a conservative variant thereof and the light chain variable region of the amino acid sequence shown in seq id No.4 or a conservative variant thereof.

According to the invention, the antibody or fragment of the antibody still retains the ability to specifically bind to the African swine fever virus P22 protein.

In a third aspect the invention provides a hybridoma cell producing an antibody or antibody fragment according to the second aspect.

According to some embodiments of the invention, the hybridoma cells secrete an antibody of the invention that specifically binds to the P22 protein of african swine fever virus.

In a fourth aspect, the invention provides a monoclonal antibody, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No.2, and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID No. 4.

According to some embodiments of the invention, the monoclonal antibody specifically binds to the african swine fever virus P22 protein.

According to some embodiments of the invention, the monoclonal antibody has an ELISA titer of 1:1024000 on ASFV P22 protein, has good reactivity, and can be used for detecting different tissues by immunohistochemistry.

According to some embodiments of the invention, the amino acid sequence of the heavy chain variable region is encoded by the base sequence shown in SEQ ID No.3 or a degenerate sequence thereof.

According to some embodiments of the invention, the amino acid sequence of the light chain variable region is encoded by the base sequence shown in SEQ ID No.5 or a degenerate sequence thereof.

In a fifth aspect the invention provides a hybridoma cell producing a monoclonal antibody according to the fourth aspect.

According to some embodiments of the invention, the hybridoma cells secrete the monoclonal antibody. The hybridoma cells can effectively secrete monoclonal antibodies, and the purity of the secreted monoclonal antibodies is high.

In a sixth aspect the invention provides a kit comprising a monoclonal antibody according to the fourth aspect.

The seventh aspect of the invention provides the use of a monoclonal antibody according to the fourth aspect or a kit according to the sixth aspect for the preparation of a medicament for the prevention or treatment of african swine fever.

The monoclonal antibody provided by the invention has good specificity on ASFV P22 protein, can be used for immunohistochemical detection of a plurality of tissues with high titer, has clean background and has wide application prospect.

Detailed Description

Hereinafter, embodiments of the present invention will be described.

The term African swine fever virus (African swine fever virus, ASFV) is the only DNA arbovirus known to date, and is a enveloped single-molecule linear double-stranded DNA virus with a genome length of about 170kb-193kb.

The term "African swine fever" (African swine fever, ASF) is an acute, febrile, highly contagious infectious disease of pigs caused by ASFV, characterized clinically by hyperpyrexia, anorexia, bleeding from skin and internal organs, and has a short course of disease and high mortality (up to 100%). The clinical symptoms of ASF are very similar to swine fever, with a latency period of 3-5 days for natural infection, which can be prolonged to 19 days, and individually up to 28 days. Depending on the virulence of the virus and the route of infection, its manifestations can be divided into 4 types, most acute, subacute and chronic: the most acute type is generally caused by a virulent strain, often dies without obvious clinical symptoms, sometimes convulsions and loss of appetite can be seen, and death occurs within hours; acute type: the sick pigs are in a deep coma state before death after the temperature is raised to 40-40.9 ℃ and is lowered for 3-5 days, and the sick pigs are in a rapid breathing, skin bleeding and high death rate after the sick pigs have no appetite and have rapid breathing in 1-2 days; subacute type: the sick pigs show cyanosis of nose, ear and abdomen and rib, have bleeding spots, cough, serous and mucinous secretion of eyes and nose, weakness of hind limbs and transient thrombocytopenia and leukopenia; chronic type: after infection, pregnant sows have abortion, diarrhea, vomiting, blood and mucus in the feces, respiratory changes and low death rate.

The term "ASFV P22 protein", also called KP177R, is a 22kD protein encoded by the ORF KP177R gene, and is the main structural protein of ASFV, and the specific function is not clear.

The term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical, except that there may be a small number of possible spontaneous mutations. Thus, the modifier "monoclonal" refers to a mixture of antibodies whose properties are not discrete. Preferably, the monoclonal antibodies include monovalent or single chain antibodies, diabodies, chimeric antibodies, humanized antibodies, and derivatives, functional equivalents and homologs of the above antibodies, as well as antibody fragments and any polypeptide comprising an antigen binding domain. Antibodies are any specific binding factor that encompasses a binding domain having the desired specificity, and thus this term encompasses antibody fragments, derivatives, humanized antibodies, and functional equivalents and homologs of antibodies that are homologous thereto, as well as any polypeptide, whether naturally or synthetically produced, that comprises an antigen binding domain. Examples of antibodies are immunoglobulin subtypes (e.g., igG, igE, igM, igD and IgA) and subtype subclasses thereof; fragments comprising an antigen binding domain such as Fab, scFv, fv, dAb, fd; and diabodies (diabodies). Chimeric molecules or equivalents comprising an antigen binding domain fused to another polypeptide are also included. Cloning and expression of chimeric antibodies is described in ep.a.0126694 and ep.a.012623. Antibodies can be modified in a number of ways and DNA recombination techniques can be used to produce other antibodies or chimeric molecules that retain the original antibody specificity. Such techniques may involve introducing DNA encoding the immunoglobulin variable or Complementarity Determining Regions (CDRs) of an antibody into the constant or constant region plus framework regions of different immunoglobulins, see ep.a.184387, GB2188638A or ep.a.239400. The hybridoma cells or other antibody-producing cells may also be subjected to genetic mutations or other alterations, which may or may not alter the binding specificity of the produced antibody. The "monoclonal antibodies" used in the present invention may also be prepared by hybridoma methods, as DNA sequences encoding the murine antibodies of the present invention may be obtained by conventional means well known to those skilled in the art, such as by artificially synthesizing nucleotide sequences from the amino acid sequences disclosed herein or amplifying them by PCR, and thus may also be obtained by recombinant DNA methods, and the sequences may be ligated into suitable expression vectors by various methods well known in the art. Finally, the transformed host cells are cultured under conditions suitable for expression of the antibodies of the invention, and then purified by conventional isolation and purification means well known to those skilled in the art to obtain the monoclonal antibodies of the invention. Antibodies comprise a geometry of polypeptide chains linked together by disulfide bridges, two polypeptide backbones, termed the light and heavy chains, constituting all major structural classes (isotypes) of antibodies. Both heavy and light chains can be further divided into several sub-regions called variable and constant regions. Heavy chains comprise a single variable region and three different constant regions, while light chains comprise a single variable region (different from the variable region of the heavy chain) and a single constant region (different from the constant region of the heavy chain). The variable regions of the heavy and light chains are responsible for the binding specificity of the antibody.

The term "antibody fragment" refers to a fragment of IgG formed by proteolytic hydrolysis. For example, papain hydrolyzes IgG to form 2 identical Fab fragments and 1 Fc fragment; pepsin hydrolyzes IgG to form 1F (ab ') 2 segment and several polypeptide fragments (pFc'). If the disulfide bond between the F (ab ') 2 heavy chains is broken, 2 Fab' fragments can be formed, which can be further digested into Fv fragments.

The term "heavy chain variable region" refers to a polypeptide which is 110 to 125 amino acids in length and whose amino acid sequence corresponds to the heavy chain amino acid sequence of a monoclonal antibody of the invention starting from the N-terminal amino acid of the heavy chain. Similarly, the term "light chain variable region" refers to a polypeptide that is 95 to 115 amino acids in length and whose amino acid sequence corresponds to the amino acid sequence of the light chain of the monoclonal antibody of the invention starting from the N-terminal amino acid of the light chain. It is obvious to one of ordinary skill in the art that, based on the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody specifically disclosed in the present invention, one or more amino acids may be added, deleted, substituted, etc. modified by conventional genetic engineering and protein engineering methods to obtain conservative variants, while still being able to maintain specific binding to african swine fever virus. Monoclonal antibodies of the invention also include active fragments or conservative variants thereof.

The term "active fragment" refers to a monoclonal antibody fragment that retains the native molecular activity of its parent and is capable of retaining specific binding to african swine fever virus.

The term "conservative variant" refers to a variant that substantially retains the properties of its parent, such as the basic immunological biological, structural, regulatory, or biochemical properties. Generally, the amino acid sequence of a conservative variant of a polypeptide differs from the parent polypeptide, but the differences are limited such that the sequence of the parent polypeptide is generally very similar to the conservative variant and is identical in many regions. The difference in amino acid sequence between the conservative variant and the parent polypeptide may be, for example: substitutions, additions and deletions of one or more amino acid residues, and any combination thereof. The amino acid residues that are replaced or inserted may or may not be encoded by the genetic code. Conservative variants of a polypeptide may occur naturally, or it may be non-naturally occurring variants. Non-naturally occurring conservative variants of a polypeptide may be produced by mutagenesis techniques or by direct synthesis.

The term "genetically engineered antibody" can be expressed by a suitable host cell by genetic engineering methods. The present invention may be used with a variety of expression host cells, such as prokaryotic host cells, including but not limited to strains of E.coli, bacillus, streptomyces, and the like; eukaryotic hosts, including but not limited to strains of Aspergillus, yeast, and the like, as well as mammalian cells, plant cells, and the like. The present invention is not limited to a specific expression vector and expression host as long as it is capable of expressing the genetically engineered antibody or a conservative variant thereof of the present invention.

The term "pig" refers to any animal belonging to a member of the porcine (Suidae) family, such as pigs.

The advantages and features of the present invention will become more apparent from the following description of the embodiments. These examples are merely exemplary and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.

The chemical reagents used in the examples of the invention are all analytically pure and purchased from the national drug group. The experimental methods provided by the invention are conventional methods unless specified; the biological material, unless otherwise specified, is commercially available.

EXAMPLE 1 African swine fever Virus P22 protein expression

1. Amplification of African swine fever virus P22 protein fragment

The African swine fever virus p22 gene sequence published by Genbank (accession number: MH 766894.1) was used as a reference, as shown in sequence 1. The synthesis of the African swine fever virus p22 protein nucleotide sequence was completed by entrusting Suzhou gold only biotechnology limited.

The primers p22-F and p22-R were used to amplify amino acids 1-191 of the p22 gene. The primers are shown in Table 1, the PCR system is shown in Table 2, and the PCR conditions are shown in Table 3.

TABLE 1 p22 protein fragment amplification primers

Primer name	Sequence (5 '-3')
		Upstream primer	p22-F：cgGGATCCATGaagaaacaacaaccaccgaaaaaggtc
Downstream primer	p22-R:cccAAGCTTttaGTGGTGGTGATGGTGGTGtgcatgtttatgatttctaggtaag

TABLE 2 PCR System

TABLE 3 PCR reaction conditions

2. Construction of African swine fever p22 protein expression donor plasmid

The PCR products amplified in step 1 were subjected to gel recovery, double digestion with restriction enzymes BamHI and HindIII (digestion system see Table 4), water-bath at 37℃for 2 hours, ligation with pFastBacI vector treated by double digestion (ligation system see Table 5), transformation of ligation products into E.coli Trans 5. Alpha. Competent cells in water-bath at 22℃for 2 hours, coating with ampicillin-containing screening resistant plates, picking up monoclonal colonies, extracting plasmids with plasmid extraction kit, and screening positive recombinant plasmids by digestion identification (double digestion identification system see Table 6). Clones with the correct insert were selected for sequencing by sequencing company. The correct positive plasmid was identified and designated pFastBac-p22.

TABLE 4 PCR products and vector double cleavage System

ddH ₂ O	Is added to 50 mu L
		10×buffer	5μL
DNA sample	2μg
		BamHI/HindIII	2.5μL/2.5μL

Table 5 connection system

10 xT 4 connection buffer	1μL
		T4 ligase	1μL
Target fragment	6μL
		Carrier body	2μL

Table 6 double enzyme digestion identification system

3. Construction of recombinant Bacmid

Transforming 5 mu L of recombinant plasmid pFastBac-p22 into DH10Bac competent cells, ice-bathing for 30min, water-bathing at 42 ℃ for 60s, ice-bathing for 2min, adding 400 mu L of SOC culture medium at 37 ℃, culturing at 200rpm for 4h, coating 100 mu L of bacterial liquid on a plate containing IPTG/X-gal/Cana/four-ring/Qingda three-antibody, culturing at 37 ℃ for at least 48h, picking a white single colony when the blue-white colony is obvious, inoculating the white single colony on a plate containing IPTG/X-gal/Cana/four-ring/Qingda three-antibody for secondary streaking, culturing at 37 ℃ for at least 12h, and picking the white single colony until the liquid LB culture medium containing Cana/four-ring/Qingda three-antibody shakes overnight. The next day 1. Mu.l was used as template and bacterial suspension PCR was performed using primers Bac13F and Bac 13R. The PCR product was identified as correct, and recombinant Bacmid was extracted using reagents from the Tiangen plasmid miniprep kit, designated Bac-p22.

4. Recombinant baculovirus acquisition and passage

Referring to the operation description of the Cellfectin II Reagent transfection kit, sf9 insect cells were transfected with recombinant Bacmid Bac-P22, cultured in a constant temperature incubator at 27℃for about 72 hours, and after cytopathic effect was apparent, the cell supernatants were harvested and labeled rBac-P22P 1.

And adding the P1 generation recombinant baculovirus into a cell culture dish paved with sf9 according to the volume ratio of 1:20-1:40, culturing at 27 ℃, and harvesting the supernatant labeled as the P2 generation recombinant baculovirus until the cytopathy is obvious for about 72 hours, and storing at 4 ℃ in a refrigerator in a dark place. The step is repeated to inoculate the recombinant baculovirus of the generation P3 and the generation P4 according to the proportion of 1:100 to 1:200.

5. Expression and purification of proteins

Recombinant baculoviruses transferred to the P4 generation were inoculated with 1L of sf9 cells at a volume ratio of 1:10-1:100, harvested from 48h-72h of inoculation, and infected cells were collected by centrifugation at 1000 Xg for 10min, and lysed with cell solution (25 mM NaHCO ₃ pH 8.3) cell pellet was lysed, and the lysate was obtained by centrifugation at 10000 Xg at 4℃for 10min, and Western Blot was performed to confirm that the target protein was expressed. And (3) carrying out affinity chromatography and molecular sieve purification by using a nickel column to obtain the target protein with a single band. Protein quantification was performed with reference to BCA protein concentration assay kit method from bi yun, ASFV P22 protein concentration of 2.2mg/ml.

Example 2 preparation, purification and identification of African swine fever Virus p22 protein monoclonal antibody

2.1 preparation and purification of monoclonal antibody of p22 protein of African swine fever virus

Purified P22 protein was subcutaneously multi-immunized in 4-6 week old female BALB/c mice, 200. Mu.l/mouse. Each immunization was performed after mixing 100. Mu.g of protein with an equal volume of adjuvant and emulsifying. Freund's complete adjuvant was used for the first immunization, freund's incomplete adjuvant was used for the second and third immunization, each immunization being separated by 2 weeks. The titer of mouse serum antibody after three-phase immunization is detected by an indirect ELISA method established by purifying P22 protein and is 1:51200.

Indirect ELISA method: the purified p22 protein was diluted to 0.5. Mu.g/mL, added to the ELISA plate, 100. Mu.l/well, and incubated at 2-8deg.C for 16-24h. The plate was washed and blocked at 37℃for 2h with 150. Mu.l of blocking solution per well. The plate was washed and diluted samples were added at 100. Mu.l/well, negative and positive controls were set simultaneously, and incubated at 37℃for 1h. The plates were washed and incubated at 37℃for 30min with the addition of HRP-labeled goat anti-mouse IgG at 100. Mu.l/well. Washing the plate, sequentially adding a developing agent A, B solution into the plate at 50 μl/hole, and developing the color at 37 ℃ for 15min; 2mol/L H were added at 50. Mu.l/well ₂ SO ₄ The reaction was terminated and the OD450nm value of each well was measured with an ELISA reader within 10 min. When OD450nm of the negative control is less than 0.2, the test is established; S/N (sample to be detected OD450 nm/negative control OD450 nm) is more than or equal to 2.1, and positive is judged; S/N is less than 2.1, and the judgment is negative; the highest dilution of the sample corresponding to the positive hole is used as the titer of the sample to be detected.

Selecting the highest antibody titer mice, performing impact immunization by injecting 100 μg of P22 protein without adjuvant into the abdominal cavity, fusing spleen of the mice with SP2/0 cells after 3 days, spreading the fused cells in 96-well cell plates containing macrophages of the abdominal cavity of the mice, and performing 5% CO at 37 DEG C ₂ Culturing in an incubator for 9-11 days, detecting the supernatant by an indirect ELISA method, subcloning positive cells by a limiting dilution method until all positive cells are obtained, obtaining 4 hybridoma cells, detecting the virus reaction of the monoclonal antibody by an IFA method, detecting that all the results are negative, and discarding all the 4 false positive hybridoma cells.

Attempts have been made to increase immunopotentiators, considering that immunization of mice with the P22 protein of african swine fever virus alone results in lower titers, which are detrimental to screening for effective monoclonal antibodies. ASFV P22 protein was mixed and emulsified 1 time with Freund's complete adjuvant in equal volumes and 10. Mu.l of Magic adjuvant of An Bi, biotech Co., ltd, and mice were immunized 2 times with P22 protein in an amount of 40. Mu.g/200. Mu.l, after which mice were immunized 2 times with P22 protein in an amount of 40. Mu.g/200. Mu.l after mixing and emulsifying ASFV P22 protein with Freund's incomplete adjuvant in equal volumes and 10. Mu.l of Magic adjuvant every 2 weeks. The antibody titer of the serum of the immunized mice is evaluated by an indirect ELISA method established by ASFV P22, 80 mug of P22 protein without adjuvant is selected for intraperitoneal injection of the mice with the highest antibody titer for boosting immunity 3 days before fusion, the ELISA titer of the serum of the mice is determined to be 1:102400, the mice are subjected to cell fusion, subcloning and screening of hybridoma cells are carried out by a limiting dilution method, finally 6 positive hybridoma cells are obtained, the monoclonal antibodies are subjected to virus reaction detection by an IFA method, the results are negative, and the 6 false positive hybridoma cells are all discarded.

The analysis of the experimental results shows that the immunopotentiator can improve the titer of the mouse serum to a certain extent, but is still unfavorable for screening effective monoclonal antibodies, so the mouse immunization program is considered to be adjusted and tracked. ASFV P22 protein was mixed and emulsified 1 time in an amount of 40. Mu.g of P22 protein/200. Mu.l of Magic adjuvant of An Bi, and then 2 times in an amount of 40. Mu.g of P22 protein/200. Mu.l of mice were immunized after mixing and emulsifying the same volumes of ASFV P22 protein and Freund's incomplete adjuvant at intervals of 1 week and 3 weeks (divided into 2 groups). The antibody titer of the serum of the immunized mice is evaluated by an indirect ELISA method established by ASFV P22, 80 mug of P22 protein without adjuvant is selected for intraperitoneal injection of the mice with the highest antibody titer 3 days before fusion for boosting, ELISA titers of the serum of the mice with the interval of 1 to 1024000 and the ELISA titers of the serum of the mice with the interval of 3 weeks are measured to be 1 to 102400 (without obvious rise), the mice with the interval of 1 week are selected for cell fusion, subcloning and screening of hybridoma cells are carried out by a limiting dilution method, and finally 10 positive hybridoma cells are obtained, wherein the ELISA titers of the cell supernatants of only 4 strains (1B 10, 4F1, 2D2 and 4B 11) are more than or equal to 1 to 6400, the residual titers are lower, and the reactivity is poor.

Ascites was prepared in mice from 4 hybridoma cells 1B10, 4F1, 2D2, and 4B11, respectively. Purifying ascites of the monoclonal antibodies 1B10, 4F1, 2D2 and 4B11 by Protein G affinity chromatography, and identifying by SDS-PAGE gel electrophoresis, wherein the purity of the monoclonal antibodies 1B10, 4F1, 2D2 and 4B11 is not lower than 85%; the BCA protein quantitative kit is used for quantitative analysis according to the specification, the concentrations of the monoclonal antibodies 1B10, 4F1, 2D2 and 4B11 are respectively 0.9mg/ml, 0.7mg/ml, 4.4mg/ml and 0.9mg/ml, wherein the yield of 3 strains of 1B10, 4F1 and 4B11 after the monoclonal antibodies are purified is lower.

2.2 monoclonal antibody identification

2.2.1 identification of monoclonal antibody types and subtypes

The subtype of monoclonal antibody 2D2 was identified using a monoclonal antibody subclass identification kit, resulting in: the heavy chain subclasses of monoclonal antibody 2D2 were IgG1 and the light chain subclasses were kappa, respectively.

2.2.2 identification of monoclonal antibody specificity

The monoclonal antibodies are respectively taken for detecting CSFV, PRRSV, PRV, PCV2, JEV and PPV by an indirect immunofluorescence method, so as to judge the specificity, and the result is that: the detection of the monoclonal antibody 2D2 is negative, which indicates that the specificity of the monoclonal antibody 2D2 is good.

2.2.3 evaluation of monoclonal antibody reactivity

The ELISA titer of monoclonal antibody 2D2 was measured by indirect ELISA (coating amount of coated primary ASFV P22 protein is 0.1. Mu.g/ml, 100. Mu.l/well) and found to be 1:1024000.

2.2.4 determination of the variable region sequence of monoclonal antibodies

According to the sequence characteristics of the murine monoclonal antibody, designing a monoclonal antibody 2D2 heavy chain variable region primer sequence:

P1：ACTAGTCGACATGAAATGCAGCTG

P2：CCAGGGRCCARKGGATARACN

designing a monoclonal antibody 2D2 light chain variable region primer sequence:

P3：ACTAGTCGACATGGAGWCAGACAC

P4：CCCAAGCTTACTGGATGGTGGG

hybridoma cells were collected, RNA was extracted and reverse transcribed as a template, and the variable region sequence was amplified using the above primers, and the amplified product was sent to Suzhou Jin Weizhi Biotechnology Co., ltd for sequencing. Results: the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 2D2 are respectively shown as SEQ.ID No.2 and SEQ.ID No. 4; the base sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody 2D2 are respectively shown as SEQ.ID No.3 and SEQ.ID No. 5.

EXAMPLE 3 African swine fever Virus p22 protein monoclonal antibody and Virus reactivity

Detecting monoclonal antibody by IFA method, recovering temperature of African swine fever virus antigen plate purchased from European African swine fever reference laboratory (Centro de Investigaci Lo n en Sanidad Animal (CISA-INIA), madrid, spain), washing with PBS for 1 time, adding monoclonal antibody 2D2, setting negative control with PBS, and placing in a 37 ℃ incubator for 1 hour; washing 3 times with PBS, adding FITC-labeled rabbit anti-mouse IgG secondary antibody, and reacting at 37deg.C for 50min; after washing 3 times with PBS, the cells were observed under a fluorescence microscope. Results: the apparent yellow-green fluorescence was seen in the cell wells of monoclonal antibody 2D2, while the negative control wells were not yellow-green, indicating that monoclonal antibody 2D2 was reactive with african swine fever virus.

EXAMPLE 4 use of African swine fever Virus p22 protein monoclonal antibody in immunohistochemistry

Tissue samples of tonsils, lungs, lymph nodes, spleen, kidneys, livers and the like of positive pigs infected by ASFV are collected and sampled by PCR, and are rapidly placed in formalin for fixation, and paraffin sections are prepared according to a conventional method. After fixing, washing with flowing water, dewatering, transparentizing, immersing in wax, embedding, slicing, spreading and mounting on treated slide, baking. Dewaxing the slide to distilled water, and dripping 3%H ₂ O ₂ Standing to inhibit endogenous enzymes. Treating the baked sheet with antigen heat repairing such as high pressure heat repairing, boiling heat repairing, microwave heat repairing, or enzyme digestionSlides to repair antigens. Washing with phosphate buffer for 3 times, and dripping blocking solution such as horse serum or bovine serum albumin BSA for blocking. After the blocking solution is sucked off, diluted primary antibody (monoclonal antibody 2D2 dilution, simultaneously with the comparison with polyclonal antibody) is added, and incubated at room temperature for 1 hour or at 37℃for 45-60 minutes or at 2-8℃overnight; washing 3 times by using phosphate buffer solution, adding the enzyme-labeled goat anti-mouse antibody as enzyme-labeled secondary antibody, and incubating for 1 hour at room temperature or 45-60 minutes at 37 ℃. Washing 3 times with phosphate buffer solution, adding AEC or DAB color development solution for color development, and stopping with phosphate buffer solution or distilled water according to the dyeing condition; hematoxylin is added to line the cell nucleus for counterstaining, dehydration, transparency, sealing and microscopic examination are carried out if necessary. And (3) result judgment: the negative control background is clear, the background is not subjected to nonspecific staining, cells of the positive control tissue are stained in red, and the test is established; the tissue cells to be detected are stained in red, namely ASFV antigen positive, otherwise negative.

Monoclonal antibody 2D2 and polyclonal antibody were diluted at a 2-fold ratio of 1:100-1:3200 and subjected to immunohistochemical detection, the results (see Table 7): compared with polyclonal antibodies, monoclonal antibody 2D2 can be used for immunohistochemical detection of a plurality of tissues with high titer, and the background is clean, and in particular, monoclonal antibody 2D2 is diluted by 1:3200-1:6400, and can also be used for detection of a plurality of tissues.

TABLE 7 immunohistochemical application comparison results

It should be noted that the above description is only a preferred embodiment of the present invention, and is not intended to limit the invention, but rather the above description is intended to limit the invention to the particular embodiment disclosed, and any and all simple modifications, equivalent changes and modifications made to the above embodiments according to the technical principles of the present invention will fall within the scope of the technical proposal of the present invention, as long as the equivalent embodiments can be changed or modified to equivalent changes without departing from the scope of the technical proposal of the present invention.

Sequence listing

<110> Luoyang Putai Biotechnology Co., ltd

<120> monoclonal antibody of African swine fever virus P22 protein and application thereof

<141> 2020-08-25

<160> 5

<170> SIPOSequenceListing 1.0

<210> 1

<211> 570

<212> DNA

<213> African swine fever virus p22 protein (Artificial sequence)

<400> 1

atgagatcct ccaaaaaaat aaacaacaaa aaaaatatgt ttaatattaa aatgacaatt 60

tctacattgc ttattgctct tattatacta cttattatta ttttagtagt gtttttatac 120

tataagaaac aacaaccacc gaaaaaggtc tgtaaagtag ataaagattg tggtagtgga 180

gagcattgtg ttcgtggatc atgtagctca ttgagctgct tagatgccgt aaaaatggac 240

aaacgaaata ttaagataga ttctaagatt tcctcatgcg aattcactcc caatttttac 300

cgttttacgg atactgctgc tgatgagcag caagaatttg gaaaaacacg gcatcctata 360

aaaataactc catctccaag tgaatcccat agcccccaag aggtgtgtga aaaatattgt 420

tcatggggaa ccgatgactg tacaggttgg gaatatgttg gtgatgaaaa ggagggaaca 480

tgttatgtat ataataatcc acatcacccg gttcttaaat atggtaagga tcacatcata 540

gccttaccta gaaatcataa acatgcataa 570

<210> 2

<211> 118

<212> PRT

<213> heavy chain variable region (Artificial sequence)

<400> 2

Glu Val Gln Leu Lys Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala

1 5 10 15

Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Leu Asn Ile Lys Gln Tyr

20 25 30

His Leu Tyr Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile

35 40 45

Gly Trp Ile Asp Pro Glu Asn Asn Asp Thr Gly Tyr Ala Pro Lys Phe

50 55 60

Gln Asp Lys Ala Ser Met Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr

65 70 75 80

Leu His Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Asn Ser Gly Thr Leu Val Ser Trp Phe Pro Tyr Trp Gly Gln Gly Thr

100 105 110

Leu Val Thr Val Ser Ala

115

<210> 3

<211> 354

<212> DNA

<213> heavy chain variable region (Artificial sequence)

<400> 3

gaggttcagc tgaagcaatc tggggcagag cttgtgaggt caggggcctc agtcaagttg 60

tcctgcacag cttctggcct caacattaaa cagtatcatt tgtattgggt gaaacagagg 120

cctgaacagg gcctggagtg gattggatgg attgatcctg aaaataatga tactgggtat 180

gccccgaagt tccaggacaa ggcctcgatg actgcagaca catcctccaa cacagcctac 240

ttgcacctca acagcctgac atctgaggac acggccgtct actactgtaa ttcagggact 300

ttggtttcct ggtttcctta ctggggccag gggactctgg tcactgtctc tgca 354

<210> 4

<211> 112

<212> PRT

<213> light chain variable region (Artificial sequence)

<400> 4

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly

1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Glu Ser

20 25 30

Gly Tyr Ser Tyr Met His Trp Tyr Gln Gln Arg Pro Gly Gln Pro Pro

35 40 45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala

50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His

65 70 75 80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Gly

85 90 95

Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys Arg

100 105 110

<210> 5

<211> 335

<212> DNA

<213> light chain variable region (Artificial sequence)

<400> 5

gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctgggtca gagggccacc 60

atctcatgca gggccagcaa aagtgtcagt gaatctggct atagttatat gcactggtac 120

caacagagac caggacagcc acccaaactc ctcatctatc ttgcatccaa cctagaatct 180

ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 240

cctgtggagg aggaggatgc tgcaacctat tactgtcagc acagtgggga gcttccgtac 300

acgttcggag gggggaccaa gctggaaatg aaacg 335

Claims

1. A monoclonal antibody or antibody fragment specifically binding to African swine fever virus P22 protein, wherein the heavy chain variable region is the amino acid sequence shown in SEQ ID No.2 and the light chain variable region is the amino acid sequence shown in SEQ ID No. 4.

2. The antibody or antibody fragment of claim 1, wherein the monoclonal antibody is one of a single chain antibody, a chimeric monoclonal antibody, and a swine monoclonal antibody.

3. The antibody or antibody fragment of claim 1 or 2, wherein the amino acid sequence of the heavy chain variable region is encoded by the base sequence set forth in SEQ ID No.3 or a degenerate sequence thereof; and/or the amino acid sequence of the light chain variable region is encoded by the base sequence shown in SEQ ID No.5 or a degenerate sequence thereof.

4. The antibody or antibody fragment of claim 3, wherein the monoclonal antibody specifically binds to the african swine fever virus P22 protein.

5. The antibody or antibody fragment according to claim 4, wherein the monoclonal antibody has an ELISA titer of 1:1024000 against the African swine fever virus P22 protein.

6. A kit comprising the monoclonal antibody of any one of claims 1-5.